U.S. Department of Veterans Affairs Begins National Rollout of WCG’s IRBNet
WCG announced that the U.S. Department of Veterans Affairs’ (VA) Office of Research and Development is successfully implementing WCG’s IRBNet electronic submission and review system for more than 100 VA medical centers (VAMCs) that have research programs.
In 2019, the VA selected IRBNet over other available solutions as the best solution to meet its complex research and compliance needs on an enterprise scale and to standardize processes among all sites. IRBNet provides technology-supported workflow, communication and documentation capabilities, assisting IRB compliance with ethical and regulatory standards for the inclusion of appropriate human subject protections, and the oversight of study conduct as mandated by federal guidelines.
“We are delighted that all the VA sites will now be using IRBNet. We specifically designed the platform to facilitate IRB compliance and increase productivity,” said Jeremy Katz, President, WCG IRBNet. “By reducing VA IRB staff’s administrative burden, IRBNet allows them to devote more time to other high priority activities, such as training and protocol development.”
For more information, click here.
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Managing Side Effects and Dosing in Off-Label GLP-1 Use with Help from Real-World Evidence
July 18th 2025Shipra Patel, global therapeutic area section head, endocrinology, global head, pediatrics, Parexel, explains how real-world data is helping researchers navigate gastrointestinal side effects, dose flexibility, and long-term tolerability in off-label GLP-1 use.
Anselamimab Misses Primary Endpoint in Phase III CARES Trials for AL Amyloidosis
July 17th 2025In the Phase III CARES trials, anselamimab did not meet the primary endpoint for advanced-stage AL amyloidosis, but a prespecified subgroup analysis revealed meaningful improvements in survival and cardiovascular outcomes.
